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Background: Hepatitis C virus infection is a major cause of cirrhosis; hepatocellular carci-
noma; and liver transplantation. The aim of this study was to estimate hepatitis C virus
disease progression and the burden of disease from a nationwide perspective.
Methods: Using a model developed to forecast hepatitis C virus disease progression and the
number of cases at each stage of liver disease; hepatitis C virus-infected population and
associated disease progression in Brazil were quantiﬁed. The impact of two  different strate-
gies  was compared: higher sustained virological response and treatment eligibility rates
(1)  or higher diagnosis and treatment rates associated with increased sustained virological
response rates (2).
Results: The number of infected individuals is estimated to decline by 35% by 2030 (1,255,000
individuals); while the number of cases of compensated (n = 325,900) and decompen-
sated  (n = 45,000) cirrhosis; hepatocellular carcinoma (n = 19,100); and liver-related deaths
(n  = 16,700) is supposed to peak between 2028 and 2032. In strategy 2; treated cases increasedover  tenfold in 2020 (118,800 treated) as compared to 2013 (11,740 treated); with sustained
virological response increased to 90% and treatment eligibility to 95%. Under this strategy;
the  number of infected individuals decreased by 90% between 2013 and 2030. Compared to
the  base case; liver-related deaths decreased by 70% by 2030; while hepatitis C virus-related
liver  cancer and decompensated cirrhosis decreased by 75 and 80%; respectively.
Abbreviations: HCV, hepatitis C virus; Anti-HCV, hepatitis C virus antibodies; HCC, hepatocellular carcinoma; IDU, injecting drug users;
AA,  direct-acting antiviral agents; SVR, sustained virological response; Peg-IFN, peguilated interferon; G1HCV, genotype 1.
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Conclusions: While the incidence and prevalence of hepatitis C virus in Brazil are decreasing;
cases of advanced liver disease continue to rise. Besides higher sustained virological
response rates; new strategies focused on increasing the proportion of diagnosed patients
and  eligibility to treatment should be adopted in order to reduce the burden of hepatitis C
virus  infection in Brazil.
© 2015 Elsevier Editora Ltda. All rights reserved.Introduction
Infection with the hepatitis C virus (HCV) is a leading cause
of cirrhosis, hepatocellular carcinoma (HCC) and liver trans-
plants in Brazil.1,2 The seroprevalence, measured by detection
of anti-HCV in large Brazilian cities, was 1.38%, which rep-
resents about two million people infected.3 However, it is
estimated that only twenty thousand HCV infected patients
are diagnosed annually in Brazil, with as few as ten thousand
being selected for treatment each year.4,5
In 2002, the Brazilian Ministry of Health created the Viral
Hepatitis National Program with goals for reducing the inci-
dence of viral hepatitis and improving the quality of life
for infected individuals.6 Harm reduction measures aimed at
reducing transmission among injecting drug users (IDU), along
with universal precautions measures for preventing noso-
comial transmission, improvement of diagnostic methods,
and distribution of medications in all regions of the coun-
try were adopted, but were insufﬁcient to decrease hepatitis
C prevalence signiﬁcantly. This observation is related to low
rate of inclusion to treatment and a small chance to cure
with interferon and ribavirine.4,5 The release of new direct-
acting antiviral agents (DAA) with lower adverse event rates,
broader eligibility criteria, and higher sustained virological
response (SVR) rates have the potential to reduce the preva-
lence, and thereby reduce transmission and new HCV cases.
Besides reducing new cases, SVR can prevent the evolution of
already infected patients to cirrhosis, advanced liver disease,
and cirrhosis decompensation, improving the quality of life
for these individuals.7 However, how much these new treat-
ment options will impact on HCV prevalence and burden in a
nationwide perspective is unknown.
The development of statistical modeling allows predicting
the long-term inﬂuence of detection rates and antiviral treat-
ments on population morbidity and mortality. These models
must be established with the relevant information to each
country in order to provide forecasts that enable interventions
in public health.8
The objectives of this study were to describe the key data
to build a statistical model for hepatitis C epidemiology in
Brazil, to analyze the current and future importance of chronic
HCV infection in the Brazilian population, and to simulate the
impact of two  possible future strategies to control hepatitis C
in Brazil.
MethodsKey parameters were gathered through a literature search:
country population, seroprevalence, viremic infectionprevalence, genotype distribution, total and annual cases
diagnosed, annual number of patients treated, and total
HCV liver transplants. When data were not available, expert
consensus or expert opinions were used to create base case
estimates.
Model
A modeling approach to describe the burden of chronic HCV
infection in Brazil was used based in a previously described
model.9 Brieﬂy, a disease progression model was constructed
in Microsoft Excel (Microsoft Corp., Redmond, WA) to quan-
tify the size of the HCV-infected population by liver disease
stages, from 1950 to 2030. Frontline Systems’ Solver, was used
to calculate the number, age and gender distribution of annual
acute infections. The model started with the annual number
of acute infections that progressed to chronic HCV infection
after accounting for spontaneous clearance of the virus. The
progression of these new cases was followed along with all
chronic infections from prior years.
Then two strategies for addressing chronic HCV infection in
Brazil and their effect on HCV-related morbidity and mortality
were considered. In strategy 1, SVR rate increases in 2014 to
80% for genotypes 1, 2 and 4, and to 70% for genotype 3. Eligibil-
ity to treatment increases to 85% in individuals infected with
genotypes 2 or 3. In 2016, medical eligibility was increased to
85% for all genotypes, and SVR to 85% for genotypes 1, 3 and
4, and 90% for genotype 2. In 2018, medical eligibility and SVR
rates were increased to 95% for all genotypes.
In strategy 2, the same treatment eligibility and SVR rates
as strategy 1 were used. However, the annual number of diag-
nosed patients increases, in 2014, to 30,000 as compared to
10,000 in 2013, and the number of treated patients increases
to 15,260 in 2014, as compared to 11,740 in 2013. In 2016,
the annual number of newly diagnosed patients increased to
90,000, and the annual number of treated patients to 30,520.
In addition, this model considers treating patients with any
HCV genotype with a Metavir ﬁbrosis score ≥F2. In 2018,
the annual diagnosed population was set at 270,000, and
annual treated population was set at 91,570. At this point all
patients with a Metavir ﬁbrosis score ≥F1 would be treated.
In 2020, the parameters includes a total of 109,880 patients
up to age 74 and any ﬁbrosis stage (Metavir ≥F0) been treated
annually.
Total  populationBrazilian population data were organized by gender and ﬁve-
year age cohorts according to United Nations population
database.10
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otal  Infected
otal HCV seroprevalence was estimated from a national study
t 1.38% in 2007, the midpoint of the data collection period
2005–2009).3 Age and gender speciﬁc HCV incidence by ﬁve-
ear age group reported by the Brazilian Ministry of Health was
sed to calculate age and gender speciﬁc prevalence rates.4
CV genotype distribution was based upon a study of blood
amples collected between 1995 and 2000 from all Brazilian
tates. This study found a distribution of 64.9, 4.6, 30.2, and
.3% for genotypes 1, 2, 3 and 4, respectively.11 (Fig. 1)
ransition  probabilities
ge and gender speciﬁc disease progression probabilities were
imulated by multiplying the total number of cases at a par-
icular stage of the disease by a progression rate to the next
tage. A more  detailed description is provided in a previously
ublished paper.9
ew  cases
o estimate changes in annual incidence over time, we used
stimates based on United States data.12 The magnitude of
ncidence, when not available for a speciﬁc year, gender or age
roup, was back-calculated based on the prevalence in 2007.3
reated  patients
n 2010, it is estimated that 11,750 patients were treated
n Brazil. We  used IMS  Health data for standard units of
eguilated interferon (Peg-IFN) sold in Brazil, with a multiplier
o account for under-reporting.5 The Brazilian genotype dis-
ribution was used to estimate the average number of weeks
f treatment per patient. After accounting for underreporting,
e  estimate that in 2010, over 372,000 units of Peg-IFN sold
n Brazil. With 85% compliance/persistence, we estimate an
verage of 31.7 units and 39.6 weeks per patient.
iver  transplantsn 2011, there were 1494 liver transplants in Brazil. Based on
xpert consensus, it is estimated that 50% of transplants were
elated to HCV in 1997, declining to 30% by 2011. This was
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validated using a regional estimate for the proportion of trans-
plants related to HCV.2
Diagnosed  patients
Based on expert consensus, the number of people living with
a diagnosis of HCV chronic infection in 2013 in Brazil was esti-
mated to be 300,000. Each year, it was estimated that 10,000
viremic individuals are newly diagnosed.
Mortality  and  risk  factors
Background mortality rates by age group and gender were cal-
culated using United Nations mortality data.13 To account for
excess mortality in the IDU population, we  estimated that
5.1% of the prevalent population are active IDU, based on
data from a national study.3 Increased mortality among active
IDU was estimated using standardized mortality ratio of 10.0
for individuals between 15 and 44 years of age.14–19 In addi-
tion, we considered excess mortality among blood transfusion
recipients. In Brazil, a national study estimated that 14.8% of
the HCV population was infected through blood transfusion.3
For this population, a standardized mortality ratio of 1.5 was
applied for all age groups.20
Results
Base  case
For the base case, the current Brazilian Ministry of Health
recommendation for HCV treatment was considered. Thus,
patients between 18 and 69 years of age have been treated.
For HCV genotype 1 (G1) infected individuals, treatment with
protease inhibitors (telaprevir or boceprevir) is supposed to
be prescribed for individuals with Metavir ﬁbrosis score ≥F3.
Individuals with G1 and lower ﬁbrosis (Metavir <F3) are eligi-
ble for treatment with Peg-IFN and ribavirin only. Individuals
infected with genotype 2 or 3 are eligible for Peg-IFN and rib-
avirin therapy regardless of ﬁbrosis score. It was estimated
that 60% of the patients that meet the above mentioned crite-
ria for treatment are medically eligible and willing to complete
treatment with Peg-IFN and ribavirin. A SVR rate of 48% was
assumed for HCV genotypes 1 and 4 treated patients,21 while
an SVR of 70% was assumed for HCV genotypes 2 and 3 treated
patients.22
Based on these inputs, the prevalence of HCV viremic indi-
viduals peaked in 1996 at 2,255,000, and a total of 1,938,700
were viremic in 2013. By 2030, it was estimated that will
be over 1,255,000 viremic HCV infected individuals in Brazil,
and over 16,600 HCV-related annual liver deaths. We  esti-
mate 45,000 cases of decompensated cirrhosis and 18,900 HCC
cases by 2030. Approximately 35% of the infected pop-
ulation will be cirrhotic or have advanced liver disease
(Fig. 2 ).Strategy  1:  increase  SVR
As a result of strategy 1 (increase in SVR only), the total num-
ber of infected individuals would decline by 46,000 in 2030
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Fig. 2 – Base case model outputs. (A) Total viremic cases, by
age, 2013; (B) Annual mortality due to liver related and
background cause, 2013–2030; (C) Number of viremic cases,
in total, and by disease stage, 1950–2030; (D) Expanded
graph of viremic cases by disease stage for cirrhosis,
decompensated cirrhosis, and hepatocellular carcinoma,
1950–2030.
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Fig. 2 – (Continued ).as compared to the base case, a 3.7% reduction. In addi-
tion, cumulative HCV-related mortality would decrease by
7570 deaths (2.5%) during 2013–2030 as compared to the base
case. Cases of HCV-related HCC and decompensated cirrhosis
would decrease by 2290 cases (5.1%) and 6030 cases (3.2%) in
2030, respectively, as compared to the base case.
Strategy 2: HCV elimination as a result of this strategy
(increase in SVR associated with an increase in HCV diagnosed
and treated individuals), the HCV infected population declines
to 190,600 individuals by 2030, an 85% decrease as compared
to the base case. Prevalent cases of decompensated cirrhosis
and liver cancer in 2030 decrease, respectively, by 36,350 (81%
decrease), and 13,810 (73% decrease) cases as compared to the
base case. Finally, cumulative HCV-related mortality from 2013
to 2030 declines by 84,880 deaths, a 28% reduction as compared
to the base case (Figs. 3 and 4).
Discussion
About 11,200 new HCV infections diagnosis occurred in Brazil
in 2013. The viremic prevalence is estimated to have peaked
in 1996 (2,255,000 individuals) and expected to decline by
45% in 2030 (1,255,000 individuals). However, the number of
cases of compensated (325,900) and decompensated (45,000)
cirrhosis, HCC (19,100), and liver-related deaths (16,700) will
peak between 2028 and 2032. These projections can be worse
if inﬂuenced by external factors, like public health system
quality.
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It is noteworthy that the time between the peak prevalence
of hepatitis C and the peak incidence of liver complications
and HCC is more  than 30 years. Consequently, the number of
elderly patients affected by this complication will be high. This
fact can bring greater complexity to the clinical care of these
patients and a worse prognosis.11
To avoid the consequences of hepatitis C burden along
time, Brazil needs a public health program with planned, con-
sistent and continued upgrade actions in next decades. It is
necessary to increase the number of centers to take care of
these patients, assign speciﬁcs tasks to primary, secondary
and tertiary levels of health care, and a network with geo-
graphical distribution (reference/counter-reference system).
The three levels of government (federal, provincial and munic-
ipal) must coordinate actions to increase identiﬁcation and
access of infected patients to treatment and care. The health
care workers must be trained in a multiprofessional approach.
The limitations of this study are mainly related to the
unavailability of Brazilian data and the assumptions already
presented. Some data from other countries were used for com-
pletion of the model. For example, the relative reduction in
observed incidence was based on United States data.11 To min-
imize this weakness, once we have gathered all the available
published data, a group of Brazilian experts was consulted for
validation.
In conclusion, the above mentioned projections, show how
important is to identify infected patients and begin treatmentespecially those with less advanced ﬁbrosis (Metavir <F3),
before they have cirrhosis, liver failure and HCC. This strategy,
based on new DAA and interferon-free regimens, should be
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adopted early, through the development and implementation
of new government guidelines. The simulation of a strat-
egy to increase detection and treatment, based on national
data, will facilitate disease forecasting, resource planning,
and rational strategies for HCV public health management in
Brazil.
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